Detalles de la búsqueda
1.
Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.
Biol Blood Marrow Transplant;
26(1): 94-106, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31493539
2.
Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant;
25(8): 1666-1673, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30986499
3.
Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.
Biol Blood Marrow Transplant;
25(3): 577-586, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30342913
4.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood;
122(25): 4129-39, 2013 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24055823
5.
High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention.
Blood Adv;
2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38669315
6.
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
J Clin Oncol;
34(10): 1112-21, 2016 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26811520
Resultados
1 -
6
de 6
1
Próxima >
>>